



02-2520 ST20 REC'D PUTTING 24 FEB 2003

102.174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
LE GAL et al
Serial No.: 09/673,166
Filed: April 4, 2001
For: LIPOPEPTIDES...VACCINATION

Group: 1614

600 Third Avenue
New York, N.Y. 10016
February 24, 2003

6 V. 24 357 3141
1416 258 6
1213 24, 2003

1213. 24, 2003
D. Muserlian

REQUEST FOR CORRECTED FILING RECEIPT

RECEIVED

Hon. Commissioner for Patents
Washington, D. C. 20231


APR 14 2003

Sir:


TECH. CENTER 1600/2900

Applicants are returning herewith the filing receipt for the above application and ask the Patent Office to issue a corrected filing receipt. There were three errors in the names of the inventors. In the first inventor, AHNE should be ANNE. In the name of the third inventor, SECAR should be SEGARD. In the name of the fourth inventor, CRAS should be Gras. We look forward to the prompt issuance of the filing receipt.

Respectfully submitted,
Muserlian, Lucas and Mercanti


Charles A. Muserlian, 19.683
Attorney for Applicants
Tel. # (212) 661-8000

CAM:ds
Enclosures

Page 1 of 2
RECEIVED**APR 14 2003**TECH. CONF. 1600/2907
Scientific Office for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/673.166	04/04/2001	1614	1148	102.174	12	21	1

20311
MUSERLIAN AND LUCAS AND MERCANTI, LLP
600 THIRD AVENUE
NEW YORK, NY 10016**CONFIRMATION NO. 2214****FILING RECEIPT**

OC00000009473235*

RECEIVED
FEB 10 2003

Date Mailed: 02/05/2003

MUSERLIAN, LUCAS AND MERCANTI LLP

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)Frederique Ahne Le Gal, Vincennes, FRANCE;
Jean Gerard Guillet, Vanves, FRANCE;
Hanne Gahery-Secard, Paris, FRANCE;
Helene Cras-Masse, Merignies, FRANCE;
Oleg Melnyk, Mons-en-Baroeul, FRANCE;
Andre Tartar, Vitry-en-Artois, FRANCE;**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/FR99/00792 04/06/1999

Foreign Applications

FRANCE 98 04323 04/07/1998

If Required, Foreign Filing License Granted: 02/04/2003**Projected Publication Date:** None. application is not eligible for pre-grant publication**Non-Publication Request:** No**Early Publication Request:** No**Title**

Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).